Trials / Completed
CompletedNCT00664898
A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma
An Open-Label, Phase Ib, Dose-Escalation Study of the Safety and Pharmacology of the Anti-CD40 Monoclonal Antibody SGN-40 Administered in Combination With Bortezomib (Velcade®, PS-341) in Patients With Relapsed or Refractory Multiple Myeloma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase Ib study to be conducted at approximately eight sites in Europe and the U.S. designed to evaluate the safety, pharmacokinetics, and activity of SGN-40 when combined with bortezomib in patients with multiple myeloma that is relapsed or refractory after at least one prior systemic treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | Escalating intravenous repeating dose |
| DRUG | SGN-40 | Escalating intravenous repeating dose |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2010-04-08
- Completion
- 2010-04-08
- First posted
- 2008-04-23
- Last updated
- 2022-12-12
Source: ClinicalTrials.gov record NCT00664898. Inclusion in this directory is not an endorsement.